Vivoryon Therapeutics N.V. Prepares for Q1 2025 Financial Update
Vivoryon Therapeutics N.V. Announces Q1 2025 Financial Results
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is gearing up to unveil its financial results for the first quarter of 2025. This announcement is pivotal as it not only reflects the company's financial health but also signals its ongoing commitment to advancing treatments for inflammatory and fibrotic disorders, primarily relating to kidney diseases.
Details of the Upcoming Financial Release
The expected date for the release of these financial results is June 17, 2025. On this day, Vivoryon will share insights from the period ending March 31, 2025, in addition to a corporate update. Investors and interested parties are invited to partake in a conference call and a public webcast.
Conference Call Information
Participants are encouraged to dial in 15 minutes before the scheduled time to ensure smooth attendance. The conference call will take place at 3:00 PM CEST and 9:00 AM EDT. Detailed instructions for joining the conference via phone will be provided, allowing seamless access to all interested stakeholders.
About Vivoryon Therapeutics N.V.
Vivoryon is a dedicated biotechnology firm focused exclusively on developing small molecule-based therapies aimed at treating serious inflammatory and fibrotic conditions associated with kidney ailments. The company is on a mission to revolutionize the treatment landscape for these disorders through innovative approaches, primarily targeting the modulation of crucial proteins that influence disease progression.
Pioneering Programs
One of Vivoryon’s groundbreaking initiatives is the advancement of varoglutamstat, a pioneering oral medication that serves as a QPCT/L inhibitor. This first-of-its-kind therapy is currently under evaluation for its effectiveness in treating diabetic kidney disease, hoping to enhance patient outcomes through its novel mechanism of action.
Investor Relations and Media Contact Information
For those seeking more information on company activities, or to engage with investor relations, Vivoryon has set forth a clear line of communication. Interested parties can reach out to:
Vivoryon Therapeutics N.V.
Dr. Manuela Bader
Director, Investor Relations & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher / Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Frequently Asked Questions
What is Vivoryon Therapeutics N.V. known for?
Vivoryon is known for developing innovative small molecule therapies targeting inflammatory and fibrotic kidney disorders.
When will Vivoryon announce its Q1 2025 financial results?
The financial results for Q1 2025 will be announced on June 17, 2025.
What is varoglutamstat?
Varoglutamstat is Vivoryon’s pioneering QPCT/L inhibitor currently being evaluated for treating diabetic kidney disease.
How can investors contact Vivoryon for more information?
Investors can reach out to Dr. Manuela Bader via email at IR@vivoryon.com for inquiries.
What is the purpose of the conference call on June 17, 2025?
The conference call is intended to discuss Q1 2025 financial results and provide corporate updates to stakeholders and the public.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
